journal article·2017-02-17Open access

Flexosomes for transdermal delivery of meloxicam: characterization and antiinflammatory activity

Abdullah H. Alomrani, Mohamed M. Badran

Abstract

The study aims to investigate the impact of flexosomes (FLs) on transdermal delivery of meloxicam (MLX). FLs are composed of phospholipid, Tween 80, and ethanol which were prepared by film hydration method. The prepared FLs were characterized for particle size, zeta potential, and entrapment efficiency (EE). Ex vivo skin penetration studies were perfomed, and the best formulation was further evaluated using in vivo antiinflammatory activity test. FLs were in nano-size scale carring negative charge and observed high EE% and enhanced skin penetration of MLX compared to conventional liposomes (CLs). The best formula was FL4 which was composedof phospholipid (10%), Tween 80 (1.5%), and ethanol (40%). FL4 showed 143.4 nm vesicle size, 84% EE, and 31-fold ex vivo permeation enhancement through skin compared to CLs. The antiinflammatory activity of FL4 gel showed significant increase compared to control. This study observed the effectiveness of using FLs as carriers for transdermal delivery of MLX.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advancements in Transdermal Drug Delivery · Lipid Membrane Structure and Behavior · Advanced Drug Delivery Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia;

Nanomedicine Unit (NMU-KSU), College of Pharmacy, King Saud University, Riyadh, Saudi Arabia;

Department of Pharmaceutics, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt

References (49)

Show source-provided references
1. 10.1016/j.colsurfb.2014.05.03010.1016/j.colsurfb.2014.05.030 ↗
2. 10.1016/j.molliq.2013.10.01510.1016/j.molliq.2013.10.015 ↗
3. 10.1016/S0928-0987(01)00167-110.1016/S0928-0987(01)00167-1 ↗
4. 10.1016/S0169-409X(02)00114-X10.1016/S0169-409X(02)00114-X ↗
5. 10.1007/s10856-015-5443-110.1007/s10856-015-5443-1 ↗
6. 10.1016/j.ijpharm.2013.08.03410.1016/j.ijpharm.2013.08.034 ↗
7. 10.1016/j.jconrel.2009.10.01610.1016/j.jconrel.2009.10.016 ↗
8. 10.1016/j.ijbiomac.2013.01.01510.1016/j.ijbiomac.2013.01.015 ↗
9. 10.1166/jbn.2010.115410.1166/jbn.2010.1154 ↗
10. 10.1016/j.ijpharm.2009.10.00610.1016/j.ijpharm.2009.10.006 ↗
11. 10.1248/bpb.b13-0057610.1248/bpb.b13-00576 ↗
12. 10.1016/j.ejpb.2007.03.00710.1016/j.ejpb.2007.03.007 ↗
13. 10.1211/jpp.58.4.000110.1211/jpp.58.4.0001 ↗
14. 10.1211/002235701177780010.1211/0022357011777800 ↗
15. 10.1016/j.ijpharm.2010.06.03410.1016/j.ijpharm.2010.06.034 ↗
16. 10.3109/10837450.2011.59816610.3109/10837450.2011.598166 ↗
17. FDA, Meloxicam Approval Document. 2000. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-938-Mobic.cfm.
18. 10.1001/archinte.160.19.294710.1001/archinte.160.19.2947 ↗
19. 10.1163/15685600577464937710.1163/156856005774649377 ↗
20. 10.1016/j.ejpb.2011.01.01110.1016/j.ejpb.2011.01.011 ↗
21. 10.1016/j.biomaterials.2007.11.01210.1016/j.biomaterials.2007.11.012 ↗
22. 10.1016/j.jconrel.2006.04.01610.1016/j.jconrel.2006.04.016 ↗
23. Kapoor BS · Int J Pharm Sci Nanotechnol · 2011 · 4 · 1497
24. 10.1016/j.lfs.2013.01.00510.1016/j.lfs.2013.01.005 ↗
25. 10.1100/2012/87405310.1100/2012/874053 ↗
26. 10.1016/j.ijpharm.2005.02.02110.1016/j.ijpharm.2005.02.021 ↗
27. 10.1016/0928-0987(95)00046-110.1016/0928-0987(95)00046-1 ↗
28. 10.1016/j.colsurfb.2014.03.01010.1016/j.colsurfb.2014.03.010 ↗
29. 10.1016/j.colsurfb.2012.10.03610.1016/j.colsurfb.2012.10.036 ↗
30. 10.1016/S0169-409X(02)00121-710.1016/S0169-409X(02)00121-7 ↗
31. Monteiro MS · Int J Nanomedicine · 2012 · 7 · 3045
32. 10.1016/j.ijpharm.2009.10.00610.1016/j.ijpharm.2009.10.006 ↗
33. 10.1016/j.bbamem.2012.10.02210.1016/j.bbamem.2012.10.022 ↗
34. Parfitt K. 1999. Martindale: The Complete Drug Reference. 32nd ed. London, United Kingdom: Pharmaceutical Press. p. 52.
35. 10.1002/jps.1012610.1002/jps.10126 ↗
36. 10.1016/j.addr.2003.10.02310.1016/j.addr.2003.10.023 ↗
37. Sanjay K · Curr Drug Del · 2008 · 8 · 207
38. 10.1016/j.nano.2011.07.01110.1016/j.nano.2011.07.011 ↗
39. 10.1111/1523-1747.ep1253509010.1111/1523-1747.ep12535090 ↗
40. 10.1016/S1359-6446(04)03180-010.1016/S1359-6446(04)03180-0 ↗
41. 10.1016/S0168-3659(99)00222-910.1016/S0168-3659(99)00222-9 ↗
42. 10.1093/rheumatology/35.suppl_1.1310.1093/rheumatology/35.suppl_1.13 ↗
43. 10.1016/S0378-5173(03)00183-210.1016/S0378-5173(03)00183-2 ↗
44. Walters KA · 1993 · 345
45. 10.3181/00379727-111-2784910.3181/00379727-111-27849 ↗
46. 10.1016/j.biopha.2015.05.00210.1016/j.biopha.2015.05.002 ↗
47. 10.1016/j.ijpharm.2014.06.00110.1016/j.ijpharm.2014.06.001 ↗
48. 10.1016/j.ijpharm.2012.07.00310.1016/j.ijpharm.2012.07.003 ↗
49. 10.1213/ANE.0b013e3182937b7410.1213/ANE.0b013e3182937b74 ↗